FHL1 interacts with oestrogen receptors and regulates breast cancer cell growth

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 1, 2011, Pages 72-85

  Ding, Lihua ^a   Niu, Chang ^a   Zheng, Yiqiong ^b   Xiong, Zhihong ^a   Liu, Yufei ^a   Lin, Jing ^b   Sun, Huiwei ^a   Huang, Ke ^b   Yang, Wen ^b   Li, Xiru ^b   Ye, Qinong ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Breast cancer; ER; FHL1; Interaction; Transcriptional activity

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FHL1 PROTEIN, HUMAN; MESSENGER RNA; MUSCLE PROTEIN; SIGNAL PEPTIDE; SMALL INTERFERING RNA;

ARTICLE; BREAST TUMOR; CELL ADHESION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DRUG ANTAGONISM; ENZYME IMMUNOASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; IMMUNOPRECIPITATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PROMOTER REGION; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; TWO HYBRID SYSTEM; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL ADHESION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; MUSCLE PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 78751693113     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00938.x     Document Type: Article

References (41)

1. Johannessen M, Moller S, Hansen T, et al The multifunctional roles of the four-and-a-half-LIM only protein FHL2. Cell Mol Life Sci. 2006; 63: 268-84.
2. Chu PH, Ruiz-Lozano P, Zhou Q, et al Expression patterns of FHL/SLIM family members suggest important functional roles in skeletal muscle and cardiovascular system. Mech Dev. 2000; 95: 259-65.
3. McGrath MJ, Mitchell CA, Coghill ID, et al Skeletal muscle LIM protein 1 (SLIM1/FHL1) induces α5b 1-integrin-dependent myocyte elongation. Am J Physiol Cell Physiol. 2003; 285: 1513-26.
4. Shen Y, Jia Z, Nagele RG, et al SRC uses Cas to suppress Fhl1 in order to promote nonanchored growth and migration of tumor cells. Cancer Res. 2006; 66: 1543-52.
5. Ding LH, Wang ZY, Yan JH, et al Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-β-like signaling pathway. J Clin Invest. 2009; 119: 349-61.
6. Ferguson AT, Davidson NE. Regulation of estrogen receptor a function in breast cancer. Crit Rev Oncog. 1997; 8: 29-46.
7. Aranda A, Pascual A. Nuclear hormone receptors and gene expression. Physiol Rev. 2001; 81: 1269-304.
8. McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science. 2002; 296: 1642-44.
9. Gustafsson JA. New insights in oestrogen receptor (ER) research-the ERβ. Eur J Cancer. 2000; 36: S16.
10. Cowley SM, Hoare S, Mosselman S, et al Estrogen receptors α and β form heterodimers on DNA. J Biol Chem. 1997; 272: 19858-62.
11. Kuiper GG, Carlsson B, Grandien K, et al Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology. 1997; 138: 863-70.
12. Pace P, Taylor J, Suntharalingam S, et al Human estrogen receptor β binds DNA in a manner similar to and dimerizes with estrogen receptor α. J Biol Chem. 1997; 272: 25832-8.
13. Kuiper GG, Lemmen JG, Carlsson B, et al Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology. 1998; 139: 4252-63.
14. Tremblay A, Tremblay GB, Labrie F, et al Ligand-independent recruitment of SRC-1 to estrogen receptor β through phosphorylation of activation function AF-1. Mol Cell. 1999: 3: 513-9.
15. Xu L, Glass CK, Rosenfeld MG. Coactivator and corepressor complexes in nuclear receptor function. Curr Opin Genet Dev. 1999; 9: 140-7.
16. Ding LH, Yan JH, Zhu JH, et al Ligand-independent activation of estrogen receptor α by XBP-1. Nucleic Acids Res. 2003; 31: 5266-74.
17. Wang XH, Yang ZH, Zhang H, et al The estrogen receptor-interacting protein HPIP increases estrogen-responsive gene expression through activation of MAPK and AKT. Biochim Biophys Acta. 2008; 1783: 1220-8.
18. Han J, Ding L, Yuan B, et al Hepatitis B virus X protein and the estrogen receptor variant lacking exon 5 inhibit estrogen receptor signaling in hepatoma cells. Nucleic Acids Res. 2006; 34: 3095-106.
19. Zhang H, Xie XY, Zhu XD, et al Stimulatory cross-talk between NFAT3 and estrogen receptor in breast cancer cells. J Biol Chem. 2005; 280: 43188-97.
20. Aiyar SE, Sun JL, Blair AL, et al Attenuation of estrogen receptor α-mediated transcription through estrogen-stimulated recruitment of a negative elongation factor. Genes Dev. 2004; 18: 2134-46.
21. Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 2001; 29: 2905-19.
22. Li X, Jia Z, Shen Y, et al Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate. Cancer Sci. 2008; 99: 1326-33.
23. Meric F, Lee WP, Sahin A, et al Expression profile of tyronsine kinases in breast cancer. Clin Cancer Res. 2002; 8: 361-67.
24. Quinzii CM, Vu TH, Min KC, et al X-linked dominant scapuloperoneal myopathy is due to a mutation in the gene encoding four-and-a-half-LIM protein 1. Am J Hum Genet. 2008; 82: 208-13.
25. Schessl J, Zou Y, McGrath MJ, et al Proteomic identification of FHL1 as the protein mutated in human reducing body myopathy. J Clin Invest. 2008; 118: 904-12.
26. Helguero LA, Faulds MH, Gustafsson JA, et al Estrogen receptors α (ERα) and β (ERβ) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene. 2005; 24: 6605-16.
27. Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y, et al Estrogen receptor (ER) β1 and ERbcx/β2 inhibit ERα function differently in breast cancer cell line MCF7. Oncogene. 2003; 22: 5011-20.
28. Stossi F, Barnett DH, Frasor J, et al Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) α or ERβ in human osteosarcoma cells: distinct and common target genes for these receptors. Endocrinology. 2004; 145: 3473-86.
29. Lavinsky RM, Jepsen K, Heinzel T, et al Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA. 1998; 95: 2920-5.
30. Karagianni P, Wong J. HDAC3: taking the SMRT-N-CoRrect road to repression. Oncogene. 2007; 26: 5439-49.
31. Cavailles V, Dauvois S, Lopez G, et al Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO J. 1995; 14: 3741-51.
32. Fan S, Wang J, Yuan R, et al BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science. 1999; 284: 1354-6.
33. Fan S, Ma YX, Wang C, et al Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene. 2001; 20: 77-87.
34. Norris JD, Fan D, Sherk A, et al A negative coregulator for the human ER. Mol Endocrinol. 2002; 16: 459-68.
35. Muller JM, Isele U, Metzger E, et al FHL2, a novel tissue-specific coactivator of the androgen receptor. EMBO J. 2000; 19: 359-69.
36. Morlon A, Sassone-Corsi P. The LIM-only protein FHL2 is a serum-inducible transcriptional coactivator of AP-1. Proc Natl Acad Sci USA. 2003; 100: 3977-82.
37. Fimia GM, De CD, Sassone-Corsi P. A family of LIM-only transcriptional coactivators: tissue-specific expression and selective activation of CREB and CREM. Mol Cell Biol. 2000; 20: 8613-22.
38. McLoughlin P, Ehler E, Carlile G, et al The LIM-only protein DRAL/FHL2 interacts with and is a corepressor for the promyelocytic leukemia zinc finger protein. J Biol Chem. 2002; 277: 37045-53.
39. Philippar U, Schratt G, Dieterich C, et al The SRF target gene Fhl2 antagonizes RhoA/MAL-dependent activation of SRF. Mol Cell. 2004; 16: 867-80.
40. Yang Y, Hou H, Haller EM, et al Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J. 2005; 24: 1021-32.
41. Kobayashi S, Shibata H, Yokota K, et al FHL2, UBC9, and PIAS1 are novel estrogen receptor α-interacting proteins. Endocr Res. 2004; 30: 617-21.